<DOC>
	<DOCNO>NCT01968187</DOCNO>
	<brief_summary>The purpose study evaluate safety effectiveness intranasal FE 992097 child adults Prader-Willi Syndrome .</brief_summary>
	<brief_title>Treatment Hyperphagia Behavioral Symptoms Children Adults Diagnosed With Prader-Willi Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Prader-Willi Syndrome</mesh_term>
	<mesh_term>Hyperphagia</mesh_term>
	<criteria>Male female 1018 year age ( inclusive ) Genetically confirm diagnosis PraderWilli Syndrome Determined nutritional phase 3 clinical assessment base Miller et al , 2011 Known genetic , hormonal , chromosomal cause cognitive impairment PraderWilli Syndrome Presence currently active psychotic symptom Presence cardiovascular disorder , epilepsy , frequent migraine severe asthma Previous diagnosis autism spectrum disorder qualify healthcare provider Prior concomitant use selective serotonin reuptake inhibitor ( SSRI ) selective norepinephrine reuptake inhibitor ( SNRI ) , antipsychotic medication , wakefulnesspromoting drug , thyroid hormone unless dosage stable â‰¥6 month time screen</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>